TG Therapeutics (TGTX) has disclosed a new risk, in the Debt & Financing category.
TG Therapeutics faces heightened business risks with government contracts, which are vulnerable to uncertain funding and stringent compliance demands. Fluctuations in government budgets may lead to reduced or withdrawn funding, impacting the company’s financial stability. Moreover, the possibility of non-renewal or abrupt termination of contracts adds to the operational uncertainty. Compliance with comprehensive procurement laws further burdens TG Therapeutics, potentially affecting its reputation, operational efficiency, and financial outcomes.
Overall, Wall Street has a Moderate Buy consensus rating on TGTX stock based on 4 Buys, 1 Sell and 1 Hold.
To learn more about TG Therapeutics’ risk factors, click here.
